← Eichor
Study identifier: NCT06507787 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive Episode. Clinical Utility and Medico-Economic Aspects

Condition: Bipolar Disorder · Major Depressive Disorder  ·  Sponsor: Alcediag

PhaseNA
Planned participants450
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission. Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn. The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide. Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the s…

This description comes directly from the study's public registry record.

Talk to the study team

Diana Vetter  ·  +33788970700  ·  diana.vetter@alcediag-alcen.com

Benjamin Dubuc  ·  benjamin.dubuc@alcediag-alcen.com

Always discuss trial participation with your own doctor first.

Locations (7)

CH ErsteinErstein, FranceNot Yet Recruiting
AP-HP Corentin CeltonIssy-les-Moulineaux, FranceNot Yet Recruiting
Etablissement Public de Santé Mentale (EPSM) 74La Roche-sur-Foron, FranceNot Yet Recruiting
Clinique Villa des RosesLyon, FranceRecruiting
Clinique Le Clos MontaigneMontrond-les-Bains, FranceRecruiting
GHU Paris Psychiatrie et NeurosciencesParis, FranceRecruiting
Clinique Médicale de Ville d'AvrayVille-d'Avray, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06507787